× The federal government has shut down due to the failures of the President and Congress to continue government funding. Millions of Californians receiving benefits from state programs may be impacted. For now, California’s Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) will continue to provide services and enroll eligible families as long as funding is available. No new federal funding to California WIC will be provided until the President and Congress take action. Families should continue to use their WIC benefits and attend their WIC appointments. This information is subject to change, so please monitor the California WIC website for updates.

Please be wary of potential highly partisan political messaging while visiting federal government websites for information related to the federal government shutdown.

Treatment-Resources-for-Providers COVID-19 Treatment Resources for Healthcare Providers

Top Menu

COVID-19 Treatment Resources for Healthcare Providers

October 2, 2024

Key point:

  • ​Effective outpatient treatment for patients with mild-to-moderate COVID-19 and at high risk for severe illness is available and should be offered to all eligible patients, with the primary goals of reducing hospitalizations and deaths. 

Overview of COVID-19 Antivirals:

The following medications are FDA approved or under EUA for the outpatient  treatment of COVID-19:

The following medications are FDA approved or under EUA for the pre-exposure prophylaxis (PReP) of COVID-19:

Introduction:

  • COVID-19 treatments can help prevent severe illness in eligible patients.
  • Eligibility depends on exposure status, symptoms, and risk factors for severe disease.  These risk factors include but are not limited to age over 50 years, being unvaccinated or not up to date on COVID-19 vaccinations, or having specific medical conditions. 
  • CDPH recommends that providers prescribe nirmatrelvir/ritonavir (Paxlovid) to non-hospitalized, symptomatic, and eligible patients. Remdesivir (Veklury) should be considered when nirmatrelvir/ritonavir (Paxlovid) is clinically contraindicated, and molnupiravir (Lagevrio) may be considered if remdesivir is impractical and Paxlovid is clinically contraindicated. ​​​​

​

​​Additional Resources: